# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

### **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant [X] Filed by a Party other than the Registrant []				
Check	Check the appropriate box:			
[]	Preliminary Proxy Statement			
[]	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))			
[]	Definitive Proxy Statement			
[X]	Definitive Additional Materials			
[]	Soliciting Material Under §240.14a-12			
	Intensity Therapeutics, Inc.			
	(Name of Registrant as Specified In Its Charter)			
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)			
Payme	Payment of Filing Fee (Check all boxes that apply):			
[X]	No fee required			
[]	Fee paid previously with preliminary materials			
[]	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11			



V75722-P32588

You invested in INTENSITY THERAPEUTICS, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on July 17, 2025.

### Get informed before you vote

View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to July 3, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



\*Please check the meeting materials for any special requirements for meeting attendance.

## THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Vo	ting Items	Board Recommends
1.	To elect one Class II director to serve a three-year term expiring in 2028.	
	Nominee:	
1a	. Mark A. Goldberg	For
2.	To ratify the appointment of EisnerAmper LLP as Intensity Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025.	For
N	<b>DTE:</b> Such other business as may properly come before the meeting or any adjournment thereof.	

V75723-P32588

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".